|
|
|
|
MVPs: Most Valuable Performers
MVPs go beyond numbers to create extraordinary value for companies and their stockholders. They are the top two to five percent of employees. In other words, if you were to lose 100 people, which two to five would you protect at all costs?
|
| |
More>>
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Bold Bets
From its origins as a small company making reproductive hormones to its current status as market leader in multiple sclerosis, Serono has always done things in a big way. The company created the infertility market with two early products: Pergonal (menotropins), used for the in vitro fertilization (IVF) of the first test-tube baby, and Profasi (chorionic gonadatropin), collected from the urine of 100,000 postmenopausal women. Serono later boldly put its MS drug Rebif (interferon beta1a) up against Biogen's Avonex, a similar interferon, in a head-to-head trial and proved Rebif's superiority.
|
| |
More>>
|
|
|
|
|
|
|
|
|
|
Scientific Expression
Back in December 2005, the New England Journal of Medicine (NEJM) issued an "Expression of Concern" over the VIGOR (Vioxx Gastrointestinal Outcomes Research) study published in 2000. The journal's editors stated that omissions regarding adverse cardiovascular events called the integrity of the study into question, and asked the VIGOR investigators to submit a correction.
|
| |
More>>
|
|
|
|
|
|
PharmExec's 2006 Forecast
Medicare Part D launches. $23 billion worth of patents expire. FDA wrestles with safety issues. Pharma prepares for unprecedented cost cutting and restructuring. 2006 promises to be banner year—if you like roller coasters.
|
| |
More>>
|
|
|
|
|
|
50 5 2005:
Five things you can do to prepare for compliance in all 50 states - starting today
Implementation of policies that respond to industry compliance standards poses a considerable burden for companies in terms of time and expense. Unless industry changes its response to state laws, the condition will worsen.
|
| |
More>>
|
|
|
|
|
|
Shedding Wings
John Hagel III advocates outsourcing as a method for building capabilities within pharma companies. But the decision to partner should be driven, not by cost reduction, but pharma executives' willingness to let go.
|
| |
More>>
|
|
|
|
|
|
|
|
|
|
|